Genetic Variants Predict Cardiovascular Effect of Intensive Glycemic Control
Researchers identified 2 genetic variants that may predict cardiovascular effects of glycemic control.
(HealthDay News) — Two genetic variants predict the cardiovascular (CV) effect of intensive glycemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, according to research published in Diabetes Care.
Hetal S. Shah, MBBS, MPH, from the Joslin Diabetes Center in Boston, and colleagues analyzed 6.8 million common variants for genome-wide association with CV mortality among 2667 white participants from the ACCORD intensive treatment arm. In the entire ACCORD white genetic dataset (5360 participants), significant loci were examined for their modulation of CV responses to glycemic treatment assignment.
The researchers identified 2 loci that attained genome-wide significance as determinants of CV mortality in the ACCORD intensive arm (10q26 and 5q13). In the entire ACCORD white genetic dataset, a genetic risk score (GRS) defined by the 2 variants was a significant modulator of CV mortality response to treatment assignment.
Participants with a GRS of 0 had a reduction in CV mortality in response to intensive treatment (hazard ratio [HR], 0.24; 95% CI, 0.07-0.86); those with a GRS of 1 had no difference (HR, 0.92; 95% CI, 0.54-1.56); and those with a GRS of 2 or greater had an increase (HR, 3.08; 95% CI, 1.82-5.21).
"Further studies are warranted to determine whether these findings can be translated into new strategies to prevent cardiovascular complications of diabetes," the researchers wrote.
Disclosures: Several pharmaceutical companies provided study medications, equipment, or supplies.